• Qiufang Deng, Baihong Pan, Hasan B Alam, Yingjian Liang, Zhenyu Wu, Baoling Liu, Nirit Mor-Vaknin, Xiuzhen Duan, Aaron M Williams, Yuzi Tian, Justin Zhang, and Yongqing Li.
• Xiangya Hospital, Central South University, Changsha, China.
• Front Immunol. 2019 Jan 1; 10: 2957.

AbstractSepsis results in millions of deaths every year, with acute lung injury (ALI) being one of the leading causes of mortality in septic patients. As neutrophil extracellular traps (NETs) are abundant in sepsis, neutralizing components of NETs may be a useful strategy to improve outcomes of sepsis. Citrullinated histone H3 (CitH3) has been recently shown to be involved in the NET formation. In this study, we demonstrate that CitH3 damages human umbilical vein endothelial cells (HUVECs) and potentiates NET formation through a positive feedback mechanism. We developed a novel CitH3 monoclonal antibody to target peptidylarginine deiminase (PAD) 2 and PAD 4 generated CitH3. In a mouse model of lethal lipopolysaccharide (LPS) induced shock, neutralizing CitH3 with the newly developed anti-CitH3 monoclonal antibody attenuates inflammatory responses, ameliorates ALI, and improves survival. Our study suggests that effectively blocking circulating CitH3 might be a potential therapeutic method for the treatment of endotoxemia.Copyright © 2020 Deng, Pan, Alam, Liang, Wu, Liu, Mor-Vaknin, Duan, Williams, Tian, Zhang and Li.

29 keywords...

hide…